Skip to main content
Harry R. Hill

Harry R. Hill, MD

Languages spoken: English

Academic Information

Departments Primary - Pathology , Primary - Pediatrics

Board Certification

  • American Board of Pathology (Anatomic & Clinical)
  • American Board of Pediatrics (Pediatrics)

Harry R. Hill, M.D. is a Professor of Pathology, Pediatrics, and Medicine, who trained in Immunology, Infectious Diseases and Clinical Laboratory Medicine at the University of Washington in Seattle and at the University of Minnesota in Minneapolis before coming to the University of Utah. Approximately 40 years ago, he established a Clinical Immunology Clinic to see primary immunodeficiency diseases such as hypogammaglobulinemia, chronic granulomatous disease, Job syndrome of Hyper IgE and recurrent infections, Wiskott Aldridge disease, the Hyper igM syndrome, isolated IgA deficiency, IgG subclass deficiencies and other disorders associate with recurrent and often severe infections. He also established a laboratory to evaluate the immunologic function in these patients, which is now a major laboratory at ARUP Laboratories, the national esoteric reference laboratory owned by the University of Utah. More recently, Dr. Hill, along with several colleagues at ARUP Laboratories, has begun to develop rapid molecular tests for some of these disorders that can be accomplished as rapidly as in 1-2 days and to use state of the art new tools such as next generation sequencing to find new causes of these primary immunodeficiencies, which can have onset from the newborn period until mid to late adulthood. Appointments can be made through the Administrative Assistant for the Division, Jeannette Rejali at 801-581-5873. The Clinical Immunology Clinic meets in Clinic 1A, which is labeled the Infectious Disease Clinic on Thursday mornings. Referral forms requesting critical clinical and laboratory data will be sent to the primary care doctor or referring specialist to speed up the workup and prevent duplication of testing. Dr. Adi Gundlapalli, is an associate of Dr. Hill's trained in immunolgy and infectious diseases, who also sees immunodeficient patients and covers for Dr. Hill when he is away. Dr. Hill has been listed in the Best Doctors in America from 1996 through 2015; he has also been funded as a researcher for 40 years from the National institutes of Health. He takes pride in spending as long as necessay deciphering the complex patients seen in this clinic. Additional benefits from evaluation in this clinic may be a better understanding of the risks of offspring and relatives developing similiar disorders.

Education History

Undergraduate Louisiana State University
Professional Medical Baylor College of Medicine
MD
Internship Emory University, Grady Memorial Hospital
Intern
Residency University of Washington School of Medicine
Resident
Fellowship University of Washington
Fellow
Chief Resident University of Washington and Harborview Medical Center
Chief Resident
Fellowship University of Minnesota Hospitals
Fellow

Selected Publications

Journal Article

  1. Hill HR, Patriarca (1982). Round table on the clinical application of leucocyte function tests. Advances in experimental medicine and biology, 141, 659-82.
  2. Pirtle EC, Hill HR, Swanson MR, van Deusen R (1976). Haemagglutination-inhibiting antibodies against swine influenza and Hong Kong influenza viruses in swine sera in the USA. Bulletin of the World Health Organization, 53(1), 7-11.
  3. Hill HR, Matsen J (1973). Newer antibiotic agents acting on gram-negative organisms. Geriatrics, 28(8), 72-6.
  4. Joshi HR, Hill HR, Asch J, Margraf RL, Coonrod E, Durtschi J, Zhou Q, He X, Voelkerding KV, Kumánovics (2021). CXXC5 variant in an immunodeficient patient with a progressive loss of hematopoietic cells. The Journal of allergy and clinical immunology, 147(4), 1504-1507.e8.
  5. Hill H (2019). Fitness genes of group A streptococci in necrotizing fasciitis and myositis. The Journal of clinical investigation, 129(2), 516-517.
  6. Hill HR, Riter ME, Menge SK, Johnson DR, Matsen J (1975). Rapid identification of group B streptococci by counterimmunoelectrophoresis. Journal of clinical microbiology, 1(2), 188-91.
  7. Hill HR, Matsen J (1983). Enzyme-linked immunosorbent assay and radioimmunoassay in the serologic diagnosis of infectious diseases. The Journal of infectious diseases, 147(2), 258-63.
  8. Joshi HR, Hill HR, Zhou Z, He X, Voelkerding KV, Kumánovics (2020). Frontline Science: Cxxc5 expression alters cell cycle and myeloid differentiation of mouse hematopoietic stem and progenitor cells. Journal of leukocyte biology, 108(2), 469-484.
  9. Kaplan EL, Hill H (1987). Return of rheumatic fever: consequences, implications, and needs. The Journal of pediatrics, 111(2), 244-6.
  10. Fischer SH, Ochs HD, Wedgwood RJ, Skvaril F, Morell A, Hill HR, Schiffmann G, Corey (1988). Survival of antigen-specific antibody following administration of intravenous immunoglobulin in patients with primary immunodeficiency diseases. Monographs in allergy, 23, 225-35.
  11. Yang KD, Hill H (1996). Immune responses to infectious diseases: an evolutionary perspective. The Pediatric infectious disease journal, 15(4), 355-64.
  12. Hill HR, Meier F (1986). Host defense factors in the gastrointestinal tract. Pediatric infectious disease, 5(1 Suppl), S144-7.
  13. Hill H (1981). Immunodeficiency diseases. Progress in clinical pathology, 8, 205-38.
  14. Anthony BF, Hill H (1988). Gram-positive bacteria: an overview and summary of session. Reviews of infectious diseases, 10 Suppl 2, S345-50.
  15. Hill H (1985). Host defenses in the neonate: prospects for enhancement. Seminars in perinatology, 9(1), 2-11.
  16. Hill H (1977). Evaluating the patient with recurrent infections. Southern medical journal, 70(2), 230-5.
  17. Eckman E, Laman JD, Fischer KF, Lopansri B, Martins TB, Hill HR, Kriesel J (2021). Spinal fluid IgG antibodies from patients with demyelinating diseases bind multiple sclerosis-associated bacteria. Journal of molecular medicine (Berlin, Germany), 99(10), 1399-1411.
  18. Liu BM, Hill H (2020). Role of Host Immune and Inflammatory Responses in COVID-19 Cases with Underlying Primary Immunodeficiency: A Review. Journal of interferon & cytokine research, 40(12), 549-554.
  19. Farmer JR, Foldvari Z, Ujhazi B, De Ravin SS, Chen K, Bleesing JJH, Schuetz C, Al-Herz W, Abraham RS, Joshi AY, Costa-Carvalho BT, Buchbinder D, Booth C, Reiff A, Ferguson PJ, Aghamohammadi A, Abolhassani H, Puck JM, Adeli M, Cancrini C, Palma P, Bertaina A, Locatelli F, Di Matteo G, Geha RS, Kanariou MG, Lycopoulou L, Tzanoudaki M, Sleasman JW, Parikh S, Pinero G, Fischer BM, Dbaibo G, Unal E, Patiroglu T, Karakukcu M, Al-Saad KK, Dilley MA, Pai SY, Dutmer CM, Gelfand EW, Geier CB, Eibl MM, Wolf HM, Henderson LA, Hazen MM, Bonfim C, Wolska-Ku'nierz B, Butte MJ, Hernandez JD, Nicholas SK, Stepensky P, Chandrakasan S, Miano M, Westermann-Clark E, Goda V, Kriván G, Holland SM, Fadugba O, Henrickson SE, Ozen A, Karakoc-Aydiner E, Baris S, Kiykim A, Bredius R, Hoeger B, Boztug K, Pashchenko O, Neven B, Moshous D, Villartay JP, Bousfiha AA, Hill HR, Notarangelo LD, Walter J (2019). Outcomes and Treatment Strategies for Autoimmunity and Hyperinflammation in Patients with RAG Deficiency. The journal of allergy and clinical immunology. In practice, 7(6), 1970-1985.e4.

Editorial

  1. Hill H (1988). Intensive control measures for streptococcal infections--is there a need?. The Western journal of medicine, 148(5), 575-6.
  2. Hill H (1979). Immunity in diabetes mellitus: impaired or enhanced?. The Western journal of medicine, 130(6), 547-50.